Table 1.
Locomotor activity during (Day 19) and after (Day 31) chronic drug infusions
| Group |
Distance traveled |
|
|---|---|---|
| Day 19 | Day 31 | |
| Taxol-Vehicle |
9108.7 ± 390.5 |
8369.0 ± 161.7 |
| Cremophor-Vehicle |
8186.0 ± 355.6 |
7843.0 ± 275.2 |
| WIN55,212-2 (0.1) |
9652.2 ± 396.2 |
8986.9 ± 1023.7 |
| WIN55,212-2 (0.5) |
9100.4 ± 312.7 |
7679.7 ± 249.0 |
| WIN-2 (0.5) + AM630 (3) |
9827.7 ± 333.9* |
9407.0 ± 273.4+ |
| WIN-2 (0.5) + AM251 (3) |
8739.3 ± 413.4 |
8699.2 ± 381.1 |
| AM1710 (0.032) |
9482.2 ± 419.9 |
8263.9 ± 423.6 |
| AM1710 (3.2) |
8637.4 ± 412.4 |
7976.1 ± 469.5 |
| AM1710 (3.2) + AM630 (3) |
8562.2 ± 364.2 |
7577.3 ± 499.3 |
| AM1710 (3.2) + AM251 (3) |
8378.1 ± 300.7 |
7269.8 ± 238.3 |
| AM630 (3) |
8016.6 ± 482.3 |
‒‒‒‒ |
| AM251 (3) | 8442.1 ± 420.1 | ‒‒‒‒ |
Data are mean ± s.e.mean (n = 4-14 per group). All groups received paclitaxel (Taxol) with the exception of the cremophor group receiving vehicle via chronic infusion. Statistical comparisons are denoted with line divisions. All divisions within the table were compared against the cremophor- and paclitaxel-vehicle control animals. WIN-2, WIN55,212-2. Doses of drugs indicated parenthetically are in mg/kg/day s.c. * P < 0.05 vs Cremophor-Vehicle, +P < 0.05 vs. Taxol-WIN55,212-2 (0.5 mg/kg/day s.c.) (ANOVA, Tukey Post Hoc).